WO2012165837A2 - 라만 분석 기반 고속 다중 약물 고속 스크리닝 장치 - Google Patents
라만 분석 기반 고속 다중 약물 고속 스크리닝 장치 Download PDFInfo
- Publication number
- WO2012165837A2 WO2012165837A2 PCT/KR2012/004223 KR2012004223W WO2012165837A2 WO 2012165837 A2 WO2012165837 A2 WO 2012165837A2 KR 2012004223 W KR2012004223 W KR 2012004223W WO 2012165837 A2 WO2012165837 A2 WO 2012165837A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- raman
- sample
- core
- detector
- drug
- Prior art date
Links
- 238000001069 Raman spectroscopy Methods 0.000 title claims abstract description 128
- 238000012216 screening Methods 0.000 title claims abstract description 76
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 229940079593 drug Drugs 0.000 title claims abstract description 43
- 238000004458 analytical method Methods 0.000 title abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 105
- 239000003086 colorant Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 69
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 claims description 23
- 230000005284 excitation Effects 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 238000004590 computer program Methods 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 230000003190 augmentative effect Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 230000003416 augmentation Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 12
- 238000001228 spectrum Methods 0.000 abstract description 11
- 239000000523 sample Substances 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 41
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 32
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 19
- 230000008569 process Effects 0.000 description 15
- 239000012491 analyte Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 239000004332 silver Substances 0.000 description 12
- 229910052709 silver Inorganic materials 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 239000010931 gold Substances 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 229910052737 gold Inorganic materials 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000002952 image-based readout Methods 0.000 description 8
- 238000013537 high throughput screening Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- -1 cofactors Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002547 new drug Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000007877 drug screening Methods 0.000 description 4
- 150000002343 gold Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002082 metal nanoparticle Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 239000010420 shell particle Substances 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000012362 drug development process Methods 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- XJGIDGNLXAJIOA-UHFFFAOYSA-N 2,11,20,29,37,38,39,40-octazanonacyclo[28.6.1.13,10.112,19.121,28.04,9.013,18.022,27.031,36]tetraconta-1(36),2,4,6,8,10(40),11,13,15,17,19,21(38),22,24,26,28,30,32,34-nonadecaen-37-amine Chemical compound Nn1c2nc3nc(nc4[nH]c(nc5nc(nc1c1ccccc21)c1ccccc51)c1ccccc41)c1ccccc31 XJGIDGNLXAJIOA-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910021387 carbon allotrope Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MNQDKWZEUULFPX-UHFFFAOYSA-M dithiazanine iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1C=CC=CC=C1N(CC)C2=CC=CC=C2S1 MNQDKWZEUULFPX-UHFFFAOYSA-M 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical group [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B21/00—Microscopes
- G02B21/36—Microscopes arranged for photographic purposes or projection purposes or digital imaging or video purposes including associated control and data processing arrangements
- G02B21/365—Control or image processing arrangements for digital or video microscopes
- G02B21/367—Control or image processing arrangements for digital or video microscopes providing an output produced by processing a plurality of individual source images, e.g. image tiling, montage, composite images, depth sectioning, image comparison
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N25/00—Circuitry of solid-state image sensors [SSIS]; Control thereof
- H04N25/70—SSIS architectures; Circuits associated therewith
- H04N25/71—Charge-coupled device [CCD] sensors; Charge-transfer registers specially adapted for CCD sensors
Definitions
- the present invention relates to a Raman assay based high speed multi-drug high speed screening device.
- Drug development is a developed country-type strategic development process, typically involving more than 10 years of long-term investment and more than $ 800 million in capital. In addition, many social infrastructures are required to do this.
- the new drug development process consists mainly of derivation and selection of action points based on basic research, selection of active substances and leading substances by compound screening, confirmation of candidate substances, clinical studies of preclinical / clinical phase 1, and commercialization of phases 2 and 3 have.
- Screening methods can generally be divided into in vitro assay methods performed in vitro and cell-based assay methods for real cells. This The compounds targeted for one screening are as small as tens of thousands for large pharmaceutical companies, all of which are used early in the screening process.
- HTS High Throughput Screening
- Rapid increases the number of compounds that can be screened per day, resulting in a shorter screening process, which saves money.
- Miniaturization is not only the best way to reduce reagent costs, but it also reduces the screening time. And can reduce the space of laboratory.
- Automation not only speeds up screening but also improves the reproducibility of results. In particular, automation is required to reduce the error of the experimenter during the screening process using 384-well or 1536-well microplates.
- Screening sensitivity The sensitivity of the detection method is directly related to the amount of sample to be used. Screening for low sensitivity samples requires more time, so detection sensitivity must be high. ' 6 Non-radioactive method: To date, about 50% of HTS methods use radioactive material. However, radioactive materials generate waste that requires special management and are uneconomical in terms of time, space and cost.
- the screening process should be as simple as possible in the liquid state, because methods that require filtration, separation, washing, extinction, and solid state require additional expense and processing.
- Pharmaceutical companies have invested heavily in compound chemical approaches and existing HTS technologies, and as a result, the number of new drug candidates has increased dramatically, and the candidates thus discovered are subject to the primary screening process (target discovery and verification, candidate discovery).
- Lower yield secondary screening process candidate material optimization).
- the difference in efficiency between the primary and secondary screening processes leads to serious bottlenecks in drug development. Therefore, maintaining the quality of data generated by secondary screening through economical expenditure above a certain level while improving efficiency and matching with the primary screening process has become a major challenge in the drug development process.
- High Content Screening can be defined as "a complex and functional screening technique based on highly sensitive fluorescent images with high resolution in time and space in various targets in living cells.”
- the underlying technology of HCS consists of detailed techniques such as cell-based assays, real-time biological cell imaging through high-resolution fluorescence measurements in time and space, and high-speed and high-content automated assays.
- HCS analysis equipment may include a Perik-Elmer Opera system of FIG. 1.
- Typical cell analysis data that can be obtained with the Opera device is as shown in FIG.
- Fluorescent labeling materials used in the fluorescence analysis have been deteriorated with fluorescence intensity over time (photobleaching).
- the wavelength of the light is very wide, which has the disadvantage of interference between different fluorescent materials.
- the number of fluorescent materials that can be used is extremely limited. Therefore, for effective high-speed drug screening, there is a need for a new method capable of multiple detection because there is no interference between materials and the peaks of the spectrum are sharp.
- Raman spectroscopy has recently attracted attention.
- Raman scattering is a spectroscopic method using a phenomenon in which the intensity of the scattering is rapidly increased by more than 10 6 to 10 8 times.
- Raman scattering When light passes through a tangible medium, some amount deviates from its inherent direction, a phenomenon known as Raman scattering.
- Raman scattering As some of the scattered light is excited by the absorption of light and the high energy levels of the electrons, the inherent stimulated light and frequency differ, and the wavelength of the Raman emission spectrum represents the chemical composition and structural properties of the light absorbing molecules in the sample.
- Raman spectroscopy can be developed into a highly sensitive technology that can directly measure a single molecule in combination with nano technology, which is currently developing at a very rapid pace, and is expected to be used as a medical sensor. I am getting it.
- This surface enhanced Raman spectroscopy (SERS) effect is related to the phenomenon of plasmon resonance, in which the metal nanoparticles exhibit distinct optical resonances in response to incident electromagnetic radiation due to the collective coupling of conducting electrons in the metal, Gold, silver, copper and other metal nanoparticles can act as miniature antennas that enhance the concentration effect of electromagnetic radiation. Molecules located near these particles exhibit much greater sensitivity to Raman spectroscopy analysis.
- Raman spectroscopy has several advantages over other analytical methods (infrared spectroscopy). Infrared spectroscopy gives a strong signal for molecules with a change in the dipole moment of the molecule, while Raman spectroscopy gives a strong signal even for nonpolar molecules with a change in the induced polarization of the molecule. Unique Raman shift (Raman Shift, cm _1 ) In addition, since it is not affected by the interference of water molecules, it is more suitable for the detection of biomolecules such as proteins and genes. However, the low signal strength did not reach a practical level despite the long research period.
- a nanoparticle including a core and a shell and having a nanogap formed between the core and the shell may be manufactured, and the analyte to be detected on the surface of the shell of the nanoparticle may be recognized.
- the biomolecules are functionalized and exposed to samples containing one or more analytes, followed by laser excitation and multiple Raman filters and detectors to obtain single or multiple Raman peaks and perform color coding correspondingly.
- An excitation module consisting of a lens, a mirror, and a pinhole to guide the light source to the microscope;
- a motion controller for controlling the change of the position of the sample, a singular or plural Raman filter for exciting the sample from the light source and filtering the light of Raman wavelength from the light scattered from the sample, and the Raman filter Microscope models for acquiring an image of a sample comprising a detector for sequentially receiving the light passing through the detection;
- the multi-drug high speed screening device may further include a storage chamber in which the core-gap-shell nanoparticles are stored.
- step 1 Adding core-gap shell nanoparticles to the sample to be detected (step 1);
- the laser beam is irradiated onto the sample to remove the core-gap-shell nanoparticles bound to the sample.
- step 2 Detecting the obtained specific Raman scattered light with a detector through a singular or plural Raman filters to obtain a single or plural phase of a sample (step 2);
- step 3 Color coding the images of the singular or plural samples obtained in step 2 into a computer program or transforming them into images of cells or biological tissues and displaying the converted images (step 3).
- step 3 Provides a multi-drug high speed screening method.
- the screening apparatus and method according to the present invention does not measure self-luminescence, but measures Raman signals generated from core-gap-shell nanoparticles, thereby eliminating interference between materials and maximizing surface enhancement Raman scattering effect.
- the use of shell nanoparticles amplifies the Raman signal approximately 10 to 12 times and results in a high reproducibility, using a CCD camera rather than a scanner as the detector to capture each well of the well plate containing the sample individually at once and in motion By moving to another well through the control of the controller to shoot again, it is possible to screen multiple drugs at high speed, multi-color coding is possible, it can be useful for various drug screening.
- FIG. 1 is a photograph showing a conventional fluorescence-based drug assay device for cell analysis.
- Figure 2 is a cell color of two colors obtained from a conventional fluorescence-based cell assay drug detector Unknown
- FIG. 3 is a conceptual diagram of a Raman spectroscopy-based high speed multi-drug fast screening device according to the present invention.
- FIG. 4 shows an exemplary core-gap-shell nanoparticle used in Raman spectroscopy based fast multi-drug fast screening method according to the present invention.
- Figure 5 is a graph measuring the surface enhanced Raman scattering spectrum with the device of the present invention using the nanoparticles prepared in Preparation Example 1-3.
- FIG. 6 is a graph showing a wavelength region of a narrow band pass filter selectively transmitting Raman light scattered from the nanoparticles prepared in Preparation Examples 1-3.
- FIG. 6 is a graph showing a wavelength region of a narrow band pass filter selectively transmitting Raman light scattered from the nanoparticles prepared in Preparation Examples 1-3.
- Figure 7 is a photograph showing that the selective imaging of each narrow band filter for selectively transmitting the Raman light scattered from the nanoparticles prepared in Preparation Examples 1-3.
- FIG. 8 is a photograph showing the sum of the images obtained by using the respective narrow-band filters for selectively transmitting the Raman light scattered from the nanoparticles prepared in Preparation Examples 1-3.
- FIG. 10 is an image of a control group (a) not adding nanoparticles to cells and a test group (b) to which PEG-coated nanoparticles prepared in Preparation Example 5 were added using the apparatus of the present invention.
- (“Filter 1" and “Filter 2”) are each measured images.
- FIG. 11 is an image obtained by measuring the cells found in the region by designating three parts in the experimental group to which the PEG-coated nanoparticles prepared in Preparation Example 4 were added. Two narrow-band filters (“Filter 1 "And” Filter 2 ”) respectively measured images.
- FIG. 12 is an image obtained by measuring the cells found in the region by designating three parts in the experimental group to which the PEG-coated nanoparticles prepared in Preparation Example 5 were added. Two narrow-band filters (“Filter 1 "And” Filter 2 ”) respectively measured images. -
- An excitation module consisting of a lens, a mirror, and a pinhole to guide the light source to the microscope;
- a motion controller for controlling the change of the position of the sample, a singular or plural Raman filter for exciting the sample from the light source and filtering the light of Raman wavelength from the light scattered from the sample, and the Raman filter
- a microscope module for acquiring an image of a sample, the detector comprising a detector for sequentially receiving light and detecting the light passing through the sample;
- the present invention provides a multi-drug high speed screening apparatus using surface augmented Raman scattering, including image processing modules that convert color images of cells or biological tissues and display the converted images.
- image processing modules that convert color images of cells or biological tissues and display the converted images.
- FIG. 3 is a conceptual diagram of a Raman spectroscopy-based high speed multi-drug fast screening device according to the present invention.
- the high speed multi-drug high speed screening device can be divided into excitation module microscope models and image processing modules. This division of role modules is only for explanatory purposes and may not be mutually exclusive and independent, and may overlap in a certain area or overlap two or more role models in a single area.
- This division of role modules is only for explanatory purposes and may not be mutually exclusive and independent, and may overlap in a certain area or overlap two or more role models in a single area.
- the excitation modules serve to guide the laser beam generated by the light source LSX10 into the microscope.
- the light source LSX10 may be a near infrared (NIR) laser or a visible light laser.
- NIR near infrared
- the visible light may have a wavelength of 400 to 700 nm, in one embodiment the visible light may be a wavelength of 514.5 nm.
- the use of visible light sources causes autofluorescence and autofluorescence leads to a reduction of the Raman signal.
- Raman image experiments using a near infrared light source have been conducted.
- the Raman signal is inversely proportional to the square of the wavelength of the light source, the intensity of the Raman signal can be increased when using a visible light source.
- the laser beam generated by the light source LSX10 passes through the spatial filter 20 to increase the beam diameter and is condensed into a range of about 10 ⁇ through a plurality of lenses, mirrors and pinholes. Can enter .
- Microscope
- the microscope module is a motion controller 50 for controlling the change of the position of the sample, using the laser beam to excite the sample, and the Raman wavelength in the light scattered from the sample. It includes a singular or plural Raman filter 40 for filtering the light, and a detector 111 that sequentially receives the light passing through the Raman filter 40.
- the optical splitter 21 may include a beamsplitter, a dichroic mirror, a detachable mirror, and the like.
- the number of single or plural Raman filters 40 for filtering the light of the Raman wavelength is preferably 1 or more and 20 or less, and preferably 5 or more and 20 or less.
- a band pass filter may be used as the Raman filter, and a narrow band pass filter is preferably used, but is not limited thereto.
- the detector 111 may be used without limitation as long as it is a detector operating in a scan method or a no scan method.
- a PMK Photomultiplier tube (APD) detector or an Avalanche photodiode (APD) detector may be used as the scan method detector.
- Avalanche photodiode (APD) detector may be used as the scan method detector.
- a scan-free detector a charge-coupled device (CCD) camera can be used.
- the sample may be a cell containing an analyte
- the analyte may be, for example, amino acids, peptides, polypeptides, proteins, glycoproteins, lipoproteins, nucleosides, nucleotides, oligonucleotides, nucleic acids, sugars.
- Carbohydrates oligosaccharides, polysaccharides, fatty acids, lipids, hormones, metabolites, cytokines, chemokines, receptors, neurotransmitters, antigens, allergens, antibodies, substrates, metabolites, cofactors, inhibitors, drugs, pharmaceuticals Water, nutrients, prions, toxins, toxins, explosives, killer, chemical weapons, biohazardous agents, radioisotopes, vitamins, heterocyclic aromatics, carcinogens, stones Mutagenic factors, anesthetics, amphetamines, barbiturates, hallucinogens, wastes or contaminants.
- the nucleic acid when the analyte is a nucleic acid, the nucleic acid may be a gene, viral RNA and DNA, bacterial DNA, bearish DNA, mammalian DNA, cDNA, mRNA, RNA and DNA fragments, oligonucleotides, synthetic oligonucleotides, modified oligonucleotides. Single- and double-stranded nucleic acids, natural and synthetic nucleic acids.
- the sample is combined with the core-gap-shell nanoparticles shown in FIG. 4 to amplify the Raman signal outside the device, or the core-gap-shell nanoparticles stored in a storage chamber (not shown) within the device may be incorporated into the sample. Can be combined by exposure.
- the core-gap-shell nanoparticles are functionalized with a biomolecule capable of recognizing the analyte to be detected on the surface of the shell, and when exposed to the sample, selectively binds to the corresponding analyte in the sample to image the form of the analyte. Done.
- biomolecules functionalized to the nanoparticles include antibodies, antibody fragments, genetically engineered antibodies, single-chain antibodies, receptor proteins, binding proteins, enzymes, inhibitor proteins, lectins, cell adhesion proteins, oligonucleotides, polynucleotides, Nucleic acids or aptamers.
- Functionalization can be a biomolecule attached to the nanoparticle surface by electrostatic attraction, directly bonded or functionalized through a linker, this method of functionalization is not particularly limited.
- the core-gap-shell nanoparticles include a core and a shell surrounding the core, and a nanogap is formed between the core and the shell, and the nose
- the fish and shell are nanoparticles connected or not connected by nanobridges, and the nano 3 ⁇ 4 contains optically active molecules.
- the optically active molecule is not limited as long as it is a molecule composed of atoms selected from the group consisting of C, H, 0, N, S and combinations thereof, and also chelates of metal ions, metal ions, and silver metal nanoparticles. Can also be used.
- the signal material used in the present invention is a broad concept encompassing fluorescent organic molecules, non-fluorescent organic molecules, inorganic nanoparticles, and Raman active components, and may include any labeling material capable of coloring without limitation.
- Raman is an active molecule.
- Raman bow component means a substance that facilitates the detection and measurement of an analyte by a Raman detection device when the nanoparticles of the present invention are attached to one or more analytes.
- Raman active molecules that can be used in Raman spectroscopy include organic atoms, molecules or inorganic atoms, molecules and the like.
- Raman active molecule FAM, Dabcyl, TAMRA, TRITC (Tet La methyl rhodamine eu 5 eu isothiocyanate), MGITC (Do ⁇ iteu green isobutyl, thiocyanate Ney bit) eu XRITC (X- Rhodamine-5-isothiocyanate), DTDC (3,3-diethylthiadicarbocyanine iodide), TRIT (tetramethyl rhodamineisothi), ⁇ 1) (7-nitrobenz-2 ⁇ 1 , 3-diazole), phthalic acid, terephthalic acid, isophthalic acid, para-aminobenzoic acid, erythrosine, biotin, digoxigenin, 5-carboxy-4 ', 5'-dichloro-2' ⁇ 7 '-Dimeux, Fluorescein, 5-carboxy-2', 4 ', 5', 5'
- the optically active molecule may be included in the nano 3 ⁇ 4, located in the inner-nanogap modified by the covalent bond or electrostatic attraction to the biomolecules functionalizing the nanoparticles, or the surface of the core particles separately from the biomolecule
- the optically active molecule can be covalently bound or electrostatically attracted.
- the optically active molecule at the nanoparticle may be located close to the core, thereby controlling the optically active molecule to be positioned at the nanogap.
- the Raman signal may vary depending on the position of the optically active molecule.
- the Raman signal may be detected most strongly, and a signal having high uniformity and reproducibility may be generated.
- a specific Raman peak is generated according to the type of optically active molecules included in the nanogap of the core-gap-shell nanoparticle, and the specific Raman peak is equal to this.
- the Raman filter detects an image of a sample (cell) by detecting it with a detector such as a CCD camera, and the image of the sample (cell) is color-coded through a computer program to be converted into an image of the sample (cell) and converted into an image. Is displayed.
- a detector such as a CCD camera
- the term "core” means a spherical or spherical particle having a diameter of 1 to 900 nm and consisting of a metal exhibiting surface plasmon resonance. Gold, silver or copper can be used as the metal exhibiting surface plasmon resonance.
- shell used in the present invention means a coating layer made of a metal exhibiting surface plasmon resonance surrounding the core, wherein the thickness of the shell is 0.1 to 900 nm, preferably 1 nm to 100. nm A nanogap is formed between the shell and the core, so that a space is formed between the core and the shell. Gold, silver, or copper may be used as the metal showing surface plasmon resonance.
- nanogap means a space formed between the core and the shell.
- the thickness of the nanogap is preferably 0.01 nm to 100 nm.
- the core and the shell may be separated by the nanogap space, the core and the shell may not be completely contacted by the nanogap, and in some regions, the core and the shell may be contacted by the nanobridge.
- nanobridge refers to a bridge existing in the nanogap connecting the core and the shell having a diameter of 0.5 to 20 nm.
- Nanoparticles of the invention may include “nanobridged nanogaps” or “nanobridgeless nanogaps” between the core and the shell.
- optically active molecule means a molecule that emits Raman scattered light by an excitation light source.
- the optically active molecule is located in the nanogap between the core and the shell having surface polarazmon resonance to maximize the surface enhanced Raman scattering effect.
- the core-gap-shell nanoparticles comprise i) a gold core and a silver shell and nanoparticles having a nanogap formed between the gold core and the silver shell, ii) a silver core and a gold shell and a silver core Nanoparticles having a nanogap formed between and a gold shell, i) a nanoparticle consisting of a gold core and a gold shell, and nanoparticles having a nanogap formed between a gold core and a gold shell, iv) a silver core and a silver shell And nanoparticles selected from the group consisting of nanoparticles having nanogaps formed between the silver shells, and most preferably, the core-gap-shell nanoparticles are composed of a gold core and a gold shell, and a gold core and gold The nanoparticles may be nanogaps formed between the shells. Also, the shape of the core particles is not limited.
- the core and the shell are in contact through the nanobridges. That is, when the shell is formed on the core, a nanogap is formed between the entire surface of the core, but in some regions, a portion of the material forming the shell may have a structure in which the nanobridge is formed in contact with the core. . This is shown in Figure 4 Likewise, a part of the shell may be formed toward the core in the process of forming the shell, whereby the nanobridges may be formed.
- the number of nanobridges is not limited as long as it can form a nanogap from one or more. 3 ⁇ 4 with a diameter of 0.5 nm to 20 mm 3 is preferred. Nanobridges help to maintain the core and shell structure more stably, and can be a factor in further increasing the signal of the SERS.
- a space is formed between the core and the shell by the nanogap, and the optically active molecules located in the nanogap are subjected to surface-enhanced Raman scattering, by the shell and shell having surface plasmon resonance.
- SERS surface-enhanced Raman scattering
- Light emitted from the sample is filtered by passing through the optical separation device 21 and through the Raman filter 40 so that only a specific Raman wavelength is detected through the detector 111.
- the Raman filter 40 may include a single or a plurality of Raman filters, through which only a specific Raman wavelength may pass, preferably 1 or more and 20 or less, more preferably 5 or more and 20 or less. By passing the light emitted from the sample sequentially through filters of different Raman wavelengths, and detecting the specific Raman wavelengths passed through the detector, one or more and 20 or less multiple phases can be obtained.
- a bandpass filter may be used as the Raman filter, and a narrowband filter is preferably used.
- the detector 111 for example, a no-scan CCD camera, may be installed with a zoom lens to adjust magnification. This enhances the optical microscope's ability to produce optical images, allowing for more detailed observation of the optical image.
- the motion controller 50 converts the point position of the sample into an x-axis or a y-axis. If a number of Raman images are obtained at one point (well) of a sample according to the number of Raman filters on a well, the motion controller 50 moves to another point (well) of the sample under the control of the motion controller 50 and the Raman image of this point. Measure In the apparatus according to the present invention, for example, when using a scanning-less CCD (Charge-coupled device) camera, each well of the well plate containing a sample is photographed individually at a time, and the motion controller By moving to another well under control and taking it again, high-speed screening is possible.
- CCD Charge-coupled device
- the microscope model may be provided with an atmosphere maintaining unit (not shown) for maintaining the atmosphere inside the outer chamber in which the sample is located, wherein the atmosphere maintaining unit controls the temperature, humidity, pH, etc. inside the chamber. can do.
- atmosphere maintaining unit not shown
- the image processing modules perform color coding on the singular or plural images obtained at the point located by the motion controller to convert the images into cells or biological tissues and display the converted images.
- the image processing models are computers. Obtained from the CCD camera
- the data is processed by the processor and the data can be stored in main storage. Data on release profiles for standard analytes may also be stored in main memory or ROM.
- the processor can confirm the analyte type of the sample by comparing the emission spectra from the analyte on the Raman active substrate.
- the processor may analyze data from the detection device to determine the identity and / or concentration of the various analytes. Differently equipped computers can be used for specific implementations. Thus, the structure of the system may be different in different embodiments of the present invention. After data collection, typically data will be sent to data analysis. To facilitate the analysis task, the data obtained by the detection device will typically be analyzed using a digital computer as described above.
- the computer can be suitably programmed for analysis and reporting of the collected data as well as for receiving and storing data from the detection device.
- One or more Raman peaks analyzed by one or more Raman filters can be color coded by software to enter different color images into each peak, converting and converting them into images of cells or biological tissues through the image with the corresponding color.
- the displayed image is displayed on the monitor.
- the device according to the present invention can obtain high resolution surface enhanced Raman scattering spectra by adding one or more core-gap-shell nanoparticles selectively bound to one or more analytes (specific cells) present in a sample, Particularly, each well of the well plate holding the sample is shot at once using a scan-cou led device (CCD) camera, and moved to another well under the control of a motion controller. By taking a picture again, multiple drugs can be screened at high speed.
- CCD scan-cou led device
- step 1 is a step of adding a reagent containing the core gap gap-shell nanoparticles to the sample containing the cells to be detected.
- the core-gap-shell nanoparticles have a biomolecule capable of recognizing the analyte (cell) to be detected on the surface of the shell, thereby exposing the sample to the sample.
- the shape can be imaged with Raman signals from nanoparticles containing optically active molecules.
- the core-gap-shell nanoparticles include i) a gold core and a silver shell, and nanoparticles having a nanogap formed between the gold core and the silver shell, ⁇ ) consisting of a core and a gold shell. Nanoparticles having a nanogap formed between the silver core and the gold shell, iii) a nanoparticle consisting of a gold core and a gold shell, and nanoparticles having a nanogap formed between the gold core and the gold shell, iv) a silver core and a silver shell. And nanoparticles selected from the group consisting of nanoparticles having nanogaps formed between the silver core and the silver shell.
- the core gap-shell nanoparticles are composed of a gold core and a gold shell and gold It may be a nanoparticle having a nanogap formed between the core and the gold shell.
- Exposure on the analyte of the core-gap-shell nanoparticles of step 1 may be performed outside the screening device according to the present invention or inside the screening device according to the present invention.
- the laser beam is irradiated to a sample to detect specific Raman scattered light obtained from the sample by a single or a plurality of Raman filters with a detector, for example, by a CCD camera to acquire images of a single or a plurality of samples.
- the screening device according to the invention is a singular or plural Raman filter, preferably 1 or more and 20 or less, more preferably 5 or more, through which only certain Raman wavelengths can pass.
- the light emitted from the sample of different Raman wavelengths By passing through the filter sequentially and detecting the specific Raman wavelength passed through the detector, multiple phases of 1 to 20 can be obtained.
- a bandpass filter may be used as the Raman filter, and a narrowband filter is preferably used.
- step 3 is a step of converting the image of cells or living tissue by color coding an image of a single or a plurality of samples obtained in Step 2 into compartment "computer program and displays a side image hwandoen.
- an image having a multiplicity of 1 color or more and 20 colors or less may be displayed by color coding a single color or a plurality of samples obtained in step 2 to a specific color through a computer according to Raman peak.
- the screening apparatus and method according to the present invention do not measure self-luminescence, but measure Raman signals generated from core-3 ⁇ 4-shell nanoparticles, thereby eliminating interference between materials and maximizing surface enhancement Raman scattering effect.
- Single DNA P nanoparticles with inner-nanogaps were prepared using the DNA strand as a Raman-dye modification platform with highly accurate position control capability in the following manner.
- DNA-modified gold nanoparticles (20 m particles; DNA sequence: Preparation Example 1 [3'-HS- (CH 2 ) 3- (Dabcyl) -A 10 -PEG 18- ⁇ CTCmGCGCAC-5 ' ], Preparation Example 2 [3'-HS- (CH 2 ) 3- (Cy3) -A 10 -PEGi 8 -AAACTCrrTGCGCAC-5 '] and Preparation Example 3
- [3'-HS- (CH 2 ) 3- (TAMRA) -A 10 -PEG 18 -CTCmGCGCAC-5'D is described in SJ Hurst, AKR Lyt ton-Jin, CA Mirkin, Anal. Chem. 78, 8313 (2006).
- the DNA-modified gold nanoparticles were replaced with a gold precursor (HAuCU), a reducing agent (NH 2 0H-HC1) and 1%.
- the gold precursor (HAuCU), the reducing agent (N3 ⁇ 40H) based on the amount of seeds (gold nanoparticles modified with DNA, 1 nM) The amount of -HC1) was adjusted.
- the DNA-modified gold nanoparticle solution (100 uL; 1 nM concentration in 0.3M PBS) was mixed with 50% 1% PVP solution.
- the solution was mixed with 1.5 y L, 5.2 l, 10.3 ii L or 30.4 hydroxy 1 amine hydrochloride solution (10 mM), respectively, and then 1.5 ⁇ , 5.2 y L, 10.3 uL or 3 ( 4 uL of chloroauric acid solution (5 mM) was mixed.
- various nanostructures were formed.
- PEG-coated gold-silver core-shell nanoparticles suitable for cell experiments on the shell surface of each nanoparticle prepared in Preparation Examples 1-3 and well dispersed in the culture medium were prepared ("Dabcyl” (Preparation) Example 4), “Cy3” (production example 5), “TAMRA” (production example 6); see FIG. 9).
- the PEG coating method was produced by introducing a protocol commonly used for gold nanoparticles.
- MPEG— SH ( ⁇ ⁇ 5 kDa) was used for the shell surface coating of the nanoparticles and mainly used in 'W. Peter Wuelfing, Stephen M. Gross, Deon T. Miles, and Royce W. Murray, J. Am. Chew. Soc. 120, 12696 (1998) Production Example 4-6 was produced with reference to the literature.
- SERS Surface-enhanced Raman scattering
- a sample for spectral measurement was prepared by spin-coating 20 ul of a cover glass on each solution containing the nanoparticles prepared in Preparation Examples 1-3 50 50 nW using an excitation laser of 660 nm as a light source.
- the excitation laser beam is concentrated on the microscope objective (> 400, 1.3 numerical aperture;> ⁇ 0, 0.5 numerical aperture; Zeiss), and the Raman signal that appears is frozen with liquid nitrogen (- 125 ° C) Collected via CCD (charge-coupled device) All data were obtained by baseline-correct ion by removing background signal to obtain surface-enhanced Raman scattering spectrum. The results are shown in FIG. It was.
- Figure 5 is a graph measuring the surface enhanced Raman scattering spectrum with the device of the present invention using the nanoparticles prepared in Preparation Example 1-3.
- the surface-enhanced Raman scattering spectrum was measured by the apparatus of the present invention using the nanoparticles prepared in Preparation Examples 1-3, and it was found that each of the nanoparticles showed different inherent peaks. there was.
- an excitation laser of 660 nm was used as a light source to find a narrow band pass filter that selectively transmits Raman light scattered from each solution containing the nanoparticles prepared in Preparation Examples 1-3.
- a narrow band pass filter that selectively transmits Raman light scattered from each solution containing the nanoparticles prepared in Preparation Examples 1-3.
- Figure 7 is a photograph showing that the selective imaging of each narrow band filter for selectively transmitting the Raman light scattered from the nanoparticles prepared in Preparation Examples 1-3.
- FIG. 8 is a photograph showing the sum of the images obtained by using the respective narrow-band filters for selectively transmitting the Raman light scattered from the nanoparticles prepared in Preparation Examples 1-3.
- Multi-color cell imaging was measured with the device of the present invention using the nanoparticles prepared in Preparation Example 4-5.
- 20,000 HeLa cells (cervical cancer cells) were seeded per well in 96 well-plates and cultured in an incubator for 20 to 24 hours. Cultured cells After washing with PBS buffer, put the cell culture containing the nanoparticles prepared in Preparation Example 4-5 and incubated for 6 hours in an incubator again. Cultured cells are washed with PBS buffer and placed in cold fixation buffer (BD cytofix TM) to fix cells for 15 minutes. After cell fixation, the fixation buffer is removed, washed twice with PBS buffer, and then PBS buffer is added again and refrigerated.
- BD cytofix TM cold fixation buffer
- FIG. 10 is an image of a control group (a) not adding nanoparticles to cells and a test group (b) to which PEG-coated nanoparticles prepared in Preparation Example 5 were added using the apparatus of the present invention. (“Filter 1" and “Filter 2”) are each measured images.
- FIG. 12 is an image obtained by measuring the cells found in the region by designating three parts in the experimental group to which the PEG-coated nanoparticles prepared in Preparation Example 5 were added.
- Two narrow-band filters (“Filter 1 "And” Filter 2 ”) respectively measured images.
- Fanter 1 "And” Filter 2 ” Two narrow-band filters
- Figure 10-12 it was confirmed that the cell image appears only in "Filter 2" that selectively transmits the signal of the PEG-coated nanoparticles prepared in Preparation Example 5. That is, this image was confirmed that the PEG-coated nanoparticles prepared in Preparation Example 5 selectively show only the images shown by adsorption to the cells, not the autofluorescence of the cells.
- optical separation device 30 objective lens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Multimedia (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Optics & Photonics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Signal Processing (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/122,975 US9459257B2 (en) | 2011-05-29 | 2012-05-29 | High-speed screening apparatus for a Raman analysis-based high-speed multiple drug |
JP2014513432A JP5917686B2 (ja) | 2011-05-29 | 2012-05-29 | ラマン分析基盤高速多重薬物高速スクリーニング装置 |
CA2837463A CA2837463C (en) | 2011-05-29 | 2012-05-29 | High-speed screening apparatus for a raman analysis-based high-speed multiple drug |
CN201280038152.XA CN103718038B (zh) | 2011-05-29 | 2012-05-29 | 高速的基于拉曼分析的多药物高速筛选装置 |
EP12794000.5A EP2717052A4 (en) | 2011-05-29 | 2012-05-29 | HIGH SPEED SCREENING DEVICE FOR A MULTI AND HIGH SPEED MEDICINE BASED ON RAMAN ANALYZES |
IL229676A IL229676A (en) | 2011-05-29 | 2013-11-28 | Instrument and method are based on Raman analysis for high-speed multidrug screening |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0050991 | 2011-05-29 | ||
KR20110050991 | 2011-05-29 | ||
KR10-2012-0056775 | 2012-05-29 | ||
KR1020120056775A KR101361652B1 (ko) | 2011-05-29 | 2012-05-29 | 라만 분석 기반 고속 다중 약물 고속 스크리닝 장치 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012165837A2 true WO2012165837A2 (ko) | 2012-12-06 |
WO2012165837A3 WO2012165837A3 (ko) | 2013-02-07 |
Family
ID=47260060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/004223 WO2012165837A2 (ko) | 2011-05-29 | 2012-05-29 | 라만 분석 기반 고속 다중 약물 고속 스크리닝 장치 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9459257B2 (ko) |
EP (1) | EP2717052A4 (ko) |
JP (1) | JP5917686B2 (ko) |
KR (1) | KR101361652B1 (ko) |
CN (1) | CN103718038B (ko) |
CA (1) | CA2837463C (ko) |
IL (1) | IL229676A (ko) |
WO (1) | WO2012165837A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015001033A1 (de) | 2015-01-27 | 2016-07-28 | Leibniz-Institut für Photonische Technologien e. V. | Hochdurchsatz-Screening-System zur Durchführung von optischen Messungen |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101467667B1 (ko) * | 2012-05-04 | 2014-12-11 | 서울대학교산학협력단 | 헤드부 및 바디부로 이루어진 나노스노우맨 형태의 나노입자, 이의 제조방법 및 이를 이용한 검출 방법 |
GB2526112A (en) * | 2014-05-14 | 2015-11-18 | Biopharm Ag R | Means and method for detection of analytes |
US10261298B1 (en) * | 2014-12-09 | 2019-04-16 | The Board Of Trustees Of The Leland Stanford Junior University | Near-infrared-II confocal microscope and methods of use |
WO2016193361A1 (en) | 2015-06-04 | 2016-12-08 | Eth Zurich | Devices, in particular optical or electro-optical devices with quantized operation |
KR102444284B1 (ko) | 2015-11-17 | 2022-09-16 | 삼성전자주식회사 | 라만 신호 측정 방법, 장치 및 라만 신호 측정 장치를 포함하는 생체 정보 분석 장치 |
WO2017221981A1 (ja) * | 2016-06-21 | 2017-12-28 | 日産化学工業株式会社 | ラマン散乱による簡易センシング法 |
CA2933860C (fr) | 2016-06-23 | 2017-08-29 | Matthieu Grosfils | Systemes et equipements permettant de controler le contenu d'un ou des compartiment(s) d'un distributeur de medicaments, methode de fabrication des systemes et equipements et methode d'utilisation correspondantes |
CN106872413B (zh) * | 2017-04-18 | 2019-09-17 | 北京航空航天大学 | 基于光瞳调制的共轴干涉表面等离子体显微方法及系统 |
CN106841122B (zh) * | 2017-04-18 | 2019-09-17 | 北京航空航天大学 | 一种免光瞳调制的共轴干涉表面等离子体显微方法及系统 |
CN107703116A (zh) * | 2017-10-18 | 2018-02-16 | 中国科学院深海科学与工程研究所 | 水下激光拉曼光谱仪 |
US12109620B2 (en) | 2018-01-10 | 2024-10-08 | Seoul National University R&Db Foundation | Plasmonic nanoparticles with intra-nanogap produced by dealloying, method for preparing the same and use thereof |
CN108169212B (zh) * | 2018-02-23 | 2019-08-20 | 华南理工大学 | 监控蔬菜农残的防氧化u型表面增强拉曼基底涂布装置及方法 |
US11137331B2 (en) * | 2018-08-21 | 2021-10-05 | Viavi Solutions Inc. | Multispectral sensor based alert condition detector |
KR102112689B1 (ko) | 2018-10-08 | 2020-05-20 | 한국표준과학연구원 | 복합 나노입자 및 이의 제조방법 |
KR102112688B1 (ko) * | 2018-10-08 | 2020-05-20 | 한국표준과학연구원 | 라만 활성 나노입자 및 이의 제조방법 |
US20220155325A1 (en) * | 2019-03-06 | 2022-05-19 | Industry-University Cooperation Foundation Hanyang University Erica Campus | Method for diagnosing alzheimer's disease using silver nanogap shell |
KR102043765B1 (ko) | 2019-04-23 | 2019-11-12 | 나노스코프시스템즈 주식회사 | 다중 측정 라만 분광기 |
US11499920B2 (en) * | 2020-03-27 | 2022-11-15 | Gemological Institute Of America, Inc. (Gia) | Imaging assisted scanning spectroscopy for gem identification |
CN113189078B (zh) * | 2021-03-04 | 2024-04-16 | 吉林大学 | 一种靶向药物的高通量筛选方法 |
CN113281337B (zh) * | 2021-06-15 | 2023-08-11 | 北京工业大学 | 一种复杂化合物拉曼光谱的提取方法 |
CN113466210B (zh) * | 2021-07-29 | 2024-04-02 | 浙江澍源智能技术有限公司 | 用于提高拉曼光谱中水信号强度的装置和方法 |
JP2023090228A (ja) * | 2021-12-17 | 2023-06-29 | 株式会社島津製作所 | ラマン顕微鏡 |
KR102749898B1 (ko) * | 2022-08-11 | 2025-01-03 | 한국재료연구원 | 고속 분자 검출이 가능한 3차원 나노플라즈모닉 기판, 검출장치, 및 검출방법 |
KR20240115636A (ko) | 2023-01-19 | 2024-07-26 | 주식회사 뷰웍스 | 표면증강 라만 산란 측정 방법 및 장치 |
IL302443A (en) * | 2023-04-25 | 2024-11-01 | Mybouncer Ltd | Apparatus for identifying presence of a substance of interest, and method of using thereof |
CN117388236B (zh) * | 2023-10-31 | 2024-05-17 | 上海默乐光检科技有限公司 | 一种高通量拉曼分子组学检测分析系统及方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018389A (en) * | 1996-07-22 | 2000-01-25 | The Regents Of The University Of California | Cone penetrometer fiber optic raman spectroscopy probe assembly |
US7267948B2 (en) | 1997-11-26 | 2007-09-11 | Ut-Battelle, Llc | SERS diagnostic platforms, methods and systems microarrays, biosensors and biochips |
US7192778B2 (en) * | 1999-10-06 | 2007-03-20 | Natan Michael J | Surface enhanced spectroscopy-active composite nanoparticles |
US8497131B2 (en) * | 1999-10-06 | 2013-07-30 | Becton, Dickinson And Company | Surface enhanced spectroscopy-active composite nanoparticles comprising Raman-active reporter molecules |
US6643012B2 (en) * | 2001-02-23 | 2003-11-04 | National University Of Singapore | Apertureless near-field scanning raman microscopy using reflection scattering geometry |
US7582415B2 (en) * | 2001-09-06 | 2009-09-01 | Don Straus | Rapid detection of replicating cells |
DE10222779A1 (de) * | 2002-05-16 | 2004-03-04 | Carl Zeiss Jena Gmbh | Verfahren und Anordnung zur Untersuchung von Proben |
GB0220063D0 (en) * | 2002-08-29 | 2002-10-09 | Isis Innovation | Magnetic particle and process for preparation |
US7588827B2 (en) * | 2003-08-18 | 2009-09-15 | Emory University | Surface enhanced Raman spectroscopy (SERS)-active composite nanoparticles, methods of fabrication thereof, and methods of use thereof |
TW200535246A (en) * | 2003-12-29 | 2005-11-01 | Intel Corp | Composite organic-inorganic nanoclusters |
US7361410B2 (en) * | 2003-12-29 | 2008-04-22 | Intel Corporation | External modification of composite organic inorganic nanoclusters comprising raman active organic compound |
JP2007534944A (ja) * | 2004-04-23 | 2007-11-29 | オクソニカ・インコーポレーテッド | 表面増強分光法活性−複合ナノ粒子 |
US20060148104A1 (en) * | 2004-10-29 | 2006-07-06 | Massachusetts Institute Of Technology | Detection of ion channel or receptor activity |
US8253936B2 (en) * | 2008-08-08 | 2012-08-28 | Chemimage Corporation | Raman characterization of transplant tissue |
JP2007147357A (ja) * | 2005-11-25 | 2007-06-14 | Nano Photon Kk | ラマン顕微鏡及びラマンスペクトルイメージの表示方法 |
KR20090009302A (ko) * | 2006-05-03 | 2009-01-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 단일 나노초승달 sers 탐침을 사용하는 프로테아제 및 프로테아제 활성의 검출 |
US7656523B2 (en) * | 2006-06-30 | 2010-02-02 | Intel Corporation | Multiplexed raman detection with filter set |
DE102006056429B3 (de) * | 2006-11-28 | 2008-02-14 | Leica Microsystems Cms Gmbh | Lasermikroskop mit räumlich trennendem Strahlteiler |
ES2500219T3 (es) | 2007-03-20 | 2014-09-30 | Becton Dickinson And Company | Ensayos que utilizan partículas activas en espectroscopia Raman potenciada en superficie (SERS) |
JP4674910B2 (ja) * | 2007-03-29 | 2011-04-20 | セキテクノトロン株式会社 | ラマン分光法による結晶多形の自動判定方法及びその装置 |
JP2010523983A (ja) * | 2007-04-02 | 2010-07-15 | エモリー ユニバーシティ | invivoにおける腫瘍ターゲティングおよび表面増強ラマンナノ粒子タグによる分光学的検出 |
EP2147295B1 (en) * | 2007-04-18 | 2019-10-16 | Sicpa Holding Sa | Sers nanotag assays |
WO2008154332A1 (en) * | 2007-06-06 | 2008-12-18 | Becton, Dickinson And Company | Near-infrared dyes as surface enhanced raman scattering reporters |
CN100520366C (zh) * | 2008-01-07 | 2009-07-29 | 首都师范大学 | 一种表面增强拉曼光谱生物探针及其制备方法 |
EP2229578A4 (en) * | 2008-01-07 | 2011-02-23 | Dynamic Throughput Inc | DISCOVERING TOOL WITH MICROFLUIDIC AND INTEGRATED BIOMARKER OPTICAL DETECTION NETWORK DEVICE, AND METHODS OF USE |
JP5175584B2 (ja) * | 2008-03-13 | 2013-04-03 | 地方独立行政法人 東京都立産業技術研究センター | 局所表面プラズモン共鳴イメージング装置 |
KR101153748B1 (ko) * | 2008-05-07 | 2012-06-14 | 재단법인서울대학교산학협력재단 | 바이오센서로 유용한 새로운 형태의 금/은 코어쉘 복합체 |
KR20100002742A (ko) * | 2008-06-30 | 2010-01-07 | 서강대학교산학협력단 | 세포 또는 생체 조직의 라만 신호 영상화 방법 및 장치 |
EP2352766A4 (en) * | 2008-11-26 | 2012-06-13 | Ca Nat Research Council | NON-GAUGES ANTIBODIES CONJUGATED AND NANOAGGREGATE EMBEDDED BEADS |
-
2012
- 2012-05-29 KR KR1020120056775A patent/KR101361652B1/ko not_active Expired - Fee Related
- 2012-05-29 US US14/122,975 patent/US9459257B2/en not_active Expired - Fee Related
- 2012-05-29 CN CN201280038152.XA patent/CN103718038B/zh not_active Expired - Fee Related
- 2012-05-29 JP JP2014513432A patent/JP5917686B2/ja active Active
- 2012-05-29 CA CA2837463A patent/CA2837463C/en not_active Expired - Fee Related
- 2012-05-29 WO PCT/KR2012/004223 patent/WO2012165837A2/ko active Application Filing
- 2012-05-29 EP EP12794000.5A patent/EP2717052A4/en not_active Withdrawn
-
2013
- 2013-11-28 IL IL229676A patent/IL229676A/en active IP Right Grant
Non-Patent Citations (8)
Title |
---|
J PHYS CHEM B, vol. 106, no. 2, 2002, pages 311 |
PHYS REV LETT, vol. 78, no. 9, 1997, pages 1667 |
S. J. HURST; A. K. R. LYTTON-JEAN; C. A. MIRKIN, ANAL. CHEM., vol. 78, 2006, pages 8313 |
SCIENCE, vol. 275, no. 5303, 1997, pages 1102 |
SCIENCE, vol. 297, 2002, pages 1536 |
SCIENCE, vol. 321, 2008, pages 388 |
See also references of EP2717052A4 |
W. PETER WUELFING; STEPHEN M. GROSS; DEON T. MILES; ROYCE W. MURRAY, J. AM. CHEM. SOC., vol. 120, 1998, pages 12696 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015001033A1 (de) | 2015-01-27 | 2016-07-28 | Leibniz-Institut für Photonische Technologien e. V. | Hochdurchsatz-Screening-System zur Durchführung von optischen Messungen |
Also Published As
Publication number | Publication date |
---|---|
JP5917686B2 (ja) | 2016-05-18 |
WO2012165837A3 (ko) | 2013-02-07 |
JP2014515496A (ja) | 2014-06-30 |
KR101361652B1 (ko) | 2014-02-14 |
CN103718038B (zh) | 2016-06-22 |
CN103718038A (zh) | 2014-04-09 |
CA2837463A1 (en) | 2012-12-06 |
KR20120132668A (ko) | 2012-12-07 |
US9459257B2 (en) | 2016-10-04 |
IL229676A0 (en) | 2014-01-30 |
EP2717052A2 (en) | 2014-04-09 |
CA2837463C (en) | 2016-08-09 |
IL229676A (en) | 2016-10-31 |
EP2717052A4 (en) | 2014-10-29 |
US20140113283A1 (en) | 2014-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101361652B1 (ko) | 라만 분석 기반 고속 다중 약물 고속 스크리닝 장치 | |
Liao et al. | Microfluidic chip coupled with optical biosensors for simultaneous detection of multiple analytes: A review | |
US7221457B2 (en) | Imaging platform for nanoparticle detection applied to SPR biomolecular interaction analysis | |
Chang et al. | Large-scale plasmonic microarrays for label-free high-throughput screening | |
JP4864088B2 (ja) | 標識不使用下での結合検出と蛍光増幅を組合せた格子に基づくセンサー及びセンサー用読取システム | |
US20060170918A1 (en) | Detection Apparatus and Detection Method for Plasmon Resonance and Fluorescence | |
US9116127B2 (en) | Quantitative determination method for target particles, photometric analysis device, and computer program for photometric analysis | |
JP4527884B2 (ja) | 化学的及び生物化学的アッセイ方法及び装置 | |
US20100177306A1 (en) | SERS Nanotag Assays | |
US20100068714A1 (en) | Multivariate detection of molecules in biossay | |
Wang et al. | Ultrasensitive and selective detection of sulfamethazine in milk via a Janus-labeled Au nanoparticle-based surface-enhanced Raman scattering-immunochromatographic assay | |
Sun | Use of microarrays as a high-throughput platform for label-free biosensing | |
Delrue et al. | The potential applications of raman spectroscopy in kidney diseases | |
Choi et al. | iSERS: from nanotag design to protein assays and ex vivo imaging | |
Markushin et al. | Sensitive detection of epithelial ovarian cancer biomarkers using tag-laser induced breakdown spectroscopy | |
JP7683329B2 (ja) | 情報処理装置、生体試料解析方法、生体試料検出装置、および生体試料検出システム | |
Wang et al. | Single extracellular vesicle research: From cell population to a single cell | |
CN117471094A (zh) | 一种基于共聚焦拉曼成像的超灵敏侧向流免疫层析试纸条 | |
KR102768840B1 (ko) | 열제어부가 통합된, turn-off 방식의 광신호 측정용 액적 로딩 카트리지 | |
Wei et al. | Ultrasensitive biosensing with single-molecule/particle digital counting | |
KR20120126459A (ko) | 다중-표적분자 동시검출용 고감도 복합-나노바이오칩 및 이를 이용한 질병진단의 정보제공방법 | |
Croop et al. | Recent advancement of light‐based single‐molecule approaches for studying biomolecules | |
Severcan et al. | Fourier transform infrared spectroscopy and imaging in cancer diagnosis and characterization | |
US20030008314A1 (en) | Fiber-optic sensor array | |
Sun | Label-free sensing on microarrays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12794000 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2837463 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14122975 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014513432 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |